| Melissa Divan Johnson, | |
|
509 Biltmore Ave, Emergency Department, Asheville, Nc (avl), NC 28801 | |
| (828) 213-1111 | |
| Not Available |
| Full Name | Melissa Divan Johnson |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 509 Biltmore Ave, Asheville, Nc (avl), North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922200955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD29307 (Oregon) | Secondary |
| 207P00000X | Emergency Medicine | 2015-00151 (North Carolina) | Primary |
| Entity Name | Transylvania Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174549208 PECOS PAC ID: 4880592427 Enrollment ID: O20031222000135 |
News Archive
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Caspase activity in the sera of patients with chronic hepatitis C infection (HCV) may be a more sensitive measure of liver injury than conventional surrogate markers like aminotransferases, according to a new study published in the November 2004 issue of Hepatology.
A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia (ALL) in children and young adults. The research appears in the New England Journal of Medicine.
Researchers at The University of Texas Health Science Center at Houston School of Public Health have been awarded a four-year, $1.3 million grant by the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health to study how the risk of asthma has changed for health care workers in Texas over the last 10 years.
› Verified 9 days ago
| Entity Name | Carolina Mountain Emergency Medicine Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457317620 PECOS PAC ID: 0345223798 Enrollment ID: O20040608001059 |
News Archive
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Caspase activity in the sera of patients with chronic hepatitis C infection (HCV) may be a more sensitive measure of liver injury than conventional surrogate markers like aminotransferases, according to a new study published in the November 2004 issue of Hepatology.
A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia (ALL) in children and young adults. The research appears in the New England Journal of Medicine.
Researchers at The University of Texas Health Science Center at Houston School of Public Health have been awarded a four-year, $1.3 million grant by the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health to study how the risk of asthma has changed for health care workers in Texas over the last 10 years.
› Verified 9 days ago
| Entity Name | The Carolinas Emergency Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477508836 PECOS PAC ID: 2567486814 Enrollment ID: O20060125000577 |
News Archive
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Caspase activity in the sera of patients with chronic hepatitis C infection (HCV) may be a more sensitive measure of liver injury than conventional surrogate markers like aminotransferases, according to a new study published in the November 2004 issue of Hepatology.
A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia (ALL) in children and young adults. The research appears in the New England Journal of Medicine.
Researchers at The University of Texas Health Science Center at Houston School of Public Health have been awarded a four-year, $1.3 million grant by the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health to study how the risk of asthma has changed for health care workers in Texas over the last 10 years.
› Verified 9 days ago
| Entity Name | Blue Ridge Regional Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679570840 PECOS PAC ID: 0648181966 Enrollment ID: O20060410000335 |
News Archive
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Caspase activity in the sera of patients with chronic hepatitis C infection (HCV) may be a more sensitive measure of liver injury than conventional surrogate markers like aminotransferases, according to a new study published in the November 2004 issue of Hepatology.
A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia (ALL) in children and young adults. The research appears in the New England Journal of Medicine.
Researchers at The University of Texas Health Science Center at Houston School of Public Health have been awarded a four-year, $1.3 million grant by the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health to study how the risk of asthma has changed for health care workers in Texas over the last 10 years.
› Verified 9 days ago
| Entity Name | Angel Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497753651 PECOS PAC ID: 9638253297 Enrollment ID: O20090312000353 |
News Archive
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Caspase activity in the sera of patients with chronic hepatitis C infection (HCV) may be a more sensitive measure of liver injury than conventional surrogate markers like aminotransferases, according to a new study published in the November 2004 issue of Hepatology.
A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia (ALL) in children and young adults. The research appears in the New England Journal of Medicine.
Researchers at The University of Texas Health Science Center at Houston School of Public Health have been awarded a four-year, $1.3 million grant by the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health to study how the risk of asthma has changed for health care workers in Texas over the last 10 years.
› Verified 9 days ago
| Entity Name | Highlands-cashiers Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851685051 PECOS PAC ID: 6103096433 Enrollment ID: O20110824000544 |
News Archive
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Caspase activity in the sera of patients with chronic hepatitis C infection (HCV) may be a more sensitive measure of liver injury than conventional surrogate markers like aminotransferases, according to a new study published in the November 2004 issue of Hepatology.
A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia (ALL) in children and young adults. The research appears in the New England Journal of Medicine.
Researchers at The University of Texas Health Science Center at Houston School of Public Health have been awarded a four-year, $1.3 million grant by the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health to study how the risk of asthma has changed for health care workers in Texas over the last 10 years.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Divan Johnson, 509 Biltmore Ave, Emergency Department, Asheville, NC 28801 Ph: (828) 213-1111 | Melissa Divan Johnson, 509 Biltmore Ave, Emergency Department, Asheville, Nc (avl), NC 28801 Ph: (828) 213-1111 |
News Archive
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Caspase activity in the sera of patients with chronic hepatitis C infection (HCV) may be a more sensitive measure of liver injury than conventional surrogate markers like aminotransferases, according to a new study published in the November 2004 issue of Hepatology.
A historic study involving researchers from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia (ALL) in children and young adults. The research appears in the New England Journal of Medicine.
Researchers at The University of Texas Health Science Center at Houston School of Public Health have been awarded a four-year, $1.3 million grant by the Centers for Disease Control and Prevention and the National Institute for Occupational Safety and Health to study how the risk of asthma has changed for health care workers in Texas over the last 10 years.
› Verified 9 days ago